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Background: Although LDL-cholesterol lowering with statins is a mainstay of current lipid modifying therapy, optimal pharmacological approach to 
patients with hypertriglyceridemia and low HDL-cholesterol remains controversial. The purpose of this study is to compare the effects of fenofibrate 
and niacin on the apolipoprotein B/A1 ratio, lipid parameters, glucose metabolism, and inflammation in those patients.
Methods: After a 4-week dietary lead-in period, 96 patient (male: 48, mean age: 60 yrs) with triglyceride of 150-500 mg, HDL-cholesterol <45 mg/
dL, and LDL-cholesterol <130 mg/dL were randomized in 2:3 ratio to one of two treatment groups for 16 weeks: fenofibrate 160 mg (group 1) or 
niacin 1500 mg (group 2) (500 mg x 4 wks, 1000 mg x 4 wks, and 1500 mg x 8 wks). At drug treatment week 16, we compared the percent change 
in the apolipoprotein B/A1 ratio, conventional lipid parameters, hemoglobin A1c, HOMA-IR, and hs-CRP from baseline.
Results: Fifty-seven patients (group 1: 29, group 2: 28) completed the study. Although mean percent change in total cholesterol (-6% vs -14%, 
p=0.03) and LDL-cholesterol (13% vs -5%, p=0.01) were significantly different, mean percent change in apolipoprotein B/A1 ratio (-17% vs -20%), 
triglyceride (-52% vs -49%), and HDL-cholesterol (22% vs 17%) were similar between the two groups. Lipoprotein (a) increased in the group 1 
whereas it decreased in the group 2 (23% vs -43%, p<0.001). Mean percent change in hemoglobin A1c (2% vs 8%, p=0.01) and HOMA-IR (-21% vs 
79%, p<0.001) were significantly different between the two groups. The reduction in hs-CRP was significantly greater in the group 2 (-28% vs -47%, 
p=0.03). Three in the group 1 and 9 in the group 2 discontinued the study due to adverse drug reactions.
Conclusions: The effect of fenofibrate 160 mg and niacin 1500 mg were similar on apolipoprotein B/A1 ratio, triglyceride, and HDL-cholesterol 
after 16-week treatment. Whereas niacin showed negative effect on glucose metabolism compared to fenofibrate, it had more beneficial effect on 
inflammation. Our results can be applicable to more individualized approach to hypertriglyceridemic patients with low HDL-cholesterol.
